Researchers behind Alzheimer's study: GLP-1 drugs show great promise

Armed with data from a phase II trial testing the efficiency of Novo Nordisk's liraglutide on Alzheimer's patients, scientists say the given drug class shows great promise for combating the disease – even though the market shows disappointment on Novo's behalf.
Photo: George Frey/Reuters/Ritzau Scanpix
Photo: George Frey/Reuters/Ritzau Scanpix

Few ailments have frustrated medical science and the pharmaceutical industry for years on end in the way Alzheimer's has, as many have tried – and failed – to develop just one efficient treatment for the disease.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading